RxDoctor Payments Data

Sophia Malary Carter, MD

Family Medicine · Miami, FLNPI 1992048656

Payments from drug & device makers

$1,634in general payments, 2019–2025

Across 60 payments — averaging $27.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$432
  • Astellas Pharma US Inc$231
  • Pfizer$160
  • Exact Sciences$138
  • Averitas Pharma Inc.$122
  • Abbott$61
  • plus $490 from 12 others

What the payments were for

  • Food & beverage$1,44088%
  • Education$19412%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,634 in reported general payments places this provider in the 70th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$18,400
Medicare patients
80
Services billed
179

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide15$14,177
MounjaroTirzepatide14$12,546
VascepaIcosapent Ethyl12$5,933
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog12$4,042
Rosuvastatin Calcium74$1,304
Nano 2nd Gen Pen NeedlePen Needle, Diabetic18$1,095
Atorvastatin Calcium92$796
Levothyroxine Sodium55$634
Famotidine34$608
Omeprazole52$599
Gabapentin40$598
Diclofenac Sodium18$451
Losartan Potassium60$421
Amlodipine Besylate68$373
ClopidogrelClopidogrel Bisulfate13$287

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$432$14,17715 claims
Lilly USA, LLCMounjaro$61$12,54614 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →